As someone who has guided many women through weight plateaus, Ive observed that the appetite reduction with GLP-1s is not just about eating lessits about regaining control
In addition, histological examination demonstrated that semaglutide reduced the altered bone structure when compared to the osteoporotic group
This article examines the regulatory status, potential hazards, and evidence-based alternatives for safe, effective weight management
Here's what the data actually shows, and where it applies
The Wegovy SmPC advises that semaglutide should be discontinued if pancreatitis is suspected Signs of gallbladder disease including right upper quadrant pain, fever, or jaundice, as GLP-1 receptor agonists and weight loss can increase the risk of gallstones Routine GP consultation is advisable for: Gastrointestinal symptoms persisting beyond 46 weeks without improvement Symptoms significantly impacting quality of life or nutritional intake Unexplained weight loss exceeding expected therapeutic effects New onset of symptoms differing from initial side effects Concerns about symptom severity or medication tolerability NICE guidance on obesity management (TA875) emphasises the importance of regular monitoring during pharmacological weight management interventions
During a womans reproductive years, estrogen encourages fat storage in specific areas, such as the hips, thighs, and buttocks